359 related articles for article (PubMed ID: 23031671)
1. Vascular endothelial growth factor a in intraocular vascular disease.
Miller JW; Le Couter J; Strauss EC; Ferrara N
Ophthalmology; 2013 Jan; 120(1):106-14. PubMed ID: 23031671
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.
Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628
[TBL] [Abstract][Full Text] [Related]
3. [Aging and retinal vascular diseases].
Takagi H
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
Pe'er J; Shweiki D; Itin A; Hemo I; Gnessin H; Keshet E
Lab Invest; 1995 Jun; 72(6):638-45. PubMed ID: 7540233
[TBL] [Abstract][Full Text] [Related]
5. Role of vascular endothelial growth factor in ocular angiogenesis.
Shams N; Ianchulev T
Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.
Aiello LP; Avery RL; Arrigg PG; Keyt BA; Jampel HD; Shah ST; Pasquale LR; Thieme H; Iwamoto MA; Park JE
N Engl J Med; 1994 Dec; 331(22):1480-7. PubMed ID: 7526212
[TBL] [Abstract][Full Text] [Related]
7. [Role of VEGF in diseases of the retina].
Barquet LA
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
[TBL] [Abstract][Full Text] [Related]
8. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
9. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion.
Park SP; Ahn JK; Mun GH
Retina; 2010 Feb; 30(2):281-6. PubMed ID: 19881397
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
11. Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization.
Behar-Cohen F; Dernigoghossian M; Andrieu-Soler C; Levy R; Cohen R; Zhao M
Drug Discov Today; 2019 Aug; 24(8):1436-1439. PubMed ID: 31173913
[TBL] [Abstract][Full Text] [Related]
12. A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
Cehofski LJ; Honoré B; Vorum H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28452939
[TBL] [Abstract][Full Text] [Related]
13. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion.
Noma H; Funatsu H; Mimura T; Harino S; Hori S
Ophthalmology; 2009 Jan; 116(1):87-93. PubMed ID: 19118700
[TBL] [Abstract][Full Text] [Related]
14. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia].
Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG
Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy.
Zhang X; Bao S; Hambly BD; Gillies MC
Int J Biochem Cell Biol; 2009 Dec; 41(12):2368-71. PubMed ID: 19646547
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability.
Peters S; Cree IA; Alexander R; Turowski P; Ockrim Z; Patel J; Boyd SR; Joussen AM; Ziemssen F; Hykin PG; Moss SE
Cytokine; 2007 Nov; 40(2):144-50. PubMed ID: 17959386
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema.
Jonas JB; Neumaier M
Ophthalmic Res; 2007; 39(3):139-42. PubMed ID: 17505145
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
Watanabe D; Suzuma K; Matsui S; Kurimoto M; Kiryu J; Kita M; Suzuma I; Ohashi H; Ojima T; Murakami T; Kobayashi T; Masuda S; Nagao M; Yoshimura N; Takagi H
N Engl J Med; 2005 Aug; 353(8):782-92. PubMed ID: 16120858
[TBL] [Abstract][Full Text] [Related]
19. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.
Witmer AN; Blaauwgeers HG; Weich HA; Alitalo K; Vrensen GF; Schlingemann RO
Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):849-57. PubMed ID: 11867607
[TBL] [Abstract][Full Text] [Related]
20. [Intraocular antiangiogenic drugs in clinical application advantages and disadvantages].
Li XX
Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):870-3. PubMed ID: 23302238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
